Roxane Laboratories Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
COLUMBUS, Ohio, Oct. 10 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Tablets, 150mg, 300mg and 600mg by the U.S. Food and Drug Administration. The product is available in bottles of 100 tablets and Unit Dose Blisters for immediate shipment to wholesalers and pharmacies nationwide.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )
Roxane Laboratories' Oxcarbazepine Tablets are AB rated to Trileptal(R) (oxcarbazepine). Annual sales of Oxcarbazepine Tablets 150mg, 300mg and 600mg are approximately $663 Million(1).
Full prescribing information for Oxcarbazepine Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.
About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.
Roxane Laboratories, Inc. is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.
(1) IMS MAT dollar sales ending 05/2007
TRILEPTAL(R) is a registered trademark of Novartis Pharmaceuticals Corporation
CONTACT: Jason Kurtz of Roxane Laboratories, +1-440-201-3668,
jkurtz@cle.boehringer-ingelheim.com
Web site: http://www.Roxane.com/
http://us.boehringer-ingelheim.com/